Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
She has held senior positions at Coca-Cola in China and PepsiCo in India
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Subscribe To Our Newsletter & Stay Updated